Date Title Description PDF
26 Jul 2023 On buy-back programmes The Company reports the commencement, effective as of today, 26 July 2023, of a share buyback program.   Download
10 May 2023 On P&L The Company releases the first quarter 2023 financial results presentation Download
10 May 2023 On P&L The Company releases the press release related to the first quarter 2023 financial results Download
25 Apr 2023 On business and financial situation ROVI commences clinical development of a new three-monthly formulation of Letrozole (Letrozole LEBE) Download
21 Feb 2023 On business and financial situation The Company releases the full year 2022 financial results presentation. Download

Pages

Date Title Description PDF
28 Dec 2021 Share buy-back , stabilisation and treasury stock programmes Share Buyback Program: transactions conducted between 20 December 2021 and 24 December 2021 Download
20 Dec 2021 Share buy-back , stabilisation and treasury stock programmes Share Buyback Program: transactions conducted between 13 December 2021 and 17 December 2021 Download
17 Dec 2021 On business and financial situation ROVI reports that the CHMP has issued a positive opinion on Okedi® for the treatment for schizophrenia Download
13 Dec 2021 Share buy-back , stabilisation and treasury stock programmes Share Buyback Program: transactions conducted between 6 December 2021 and 10 December 2021 Download
06 Dec 2021 Share buy-back , stabilisation and treasury stock programmes Share Buyback Program: transactions conducted between 29 November 2021 and 3 December 2021 Download

Pages

Date Title Description PDF
09 Oct 2015 Otros sobre operaciones corporativas Download
08 Oct 2015 Otros sobre operaciones corporativas Download
30 Jul 2015 Información sobre resultados (2) Download
30 Jul 2015 Información sobre resultados Download
30 Jun 2015 Información sobre dividendos Download

Pages